Central Nervous System Pharmacology Practice Questions

Q: Which of the following statements regarding benzodiazepines is true?

These act as GABA facilitators.. ### Explanation **Correct Option: C. These act as GABA facilitators.** Benzodiazepines (BZDs) work by binding to a specific site on the **GABA-A receptor** (between the $\alpha$ and $\gamma$ subunits). They do not activate the receptor directly; instead, they act as **positive allosteric modulators**. They increase the **frequency** of chloride channel opening in the presence of GABA, leading to hyperpolarization of the neuron. This enhancement of GABA’s inhibitory effect is why they are termed "GABA facilitators." **Why other options are incorrect:** * **A. These are very unsafe drugs:** BZDs are relatively safe compared to older sedatives like barbiturates. They have a high therapeutic index and rarely cause fatal respiratory depression unless combined with other CNS depressants (like alcohol). * **B. These are powerful enzyme inducers:** Unlike barbiturates (which are potent microsomal enzyme inducers), BZDs **do not induce hepatic enzymes**. This makes them safer regarding drug-drug interactions. * **D. The antidote for these is protamine sulfate:** Protamine sulfate is the antidote for Heparin. The specific competitive antagonist for benzodiazepine overdose is **Flumazenil**. **High-Yield NEET-PG Pearls:** * **Mechanism Distinction:** BZDs increase the **frequency** of channel opening, while Barbiturates increase the **duration** of channel opening. * **Metabolism:** Most BZDs are metabolized by Phase I (oxidation) and Phase II (glucuronidation) reactions. However, **L-O-T** drugs (**L**orazepam, **O**xazepam, **T**emazepam) undergo only Phase II reactions, making them safer in elderly patients or those with liver failure. * **Drug of Choice:** BZDs are the DOC for **Status Epilepticus** (Lorazepam/Diazepam) and **Alcohol Withdrawal** (Chlordiazepoxide).

Q: Pegvisomant is approved for the treatment of which condition?

Acromegaly. **Explanation:** **Pegvisomant** is a genetically modified analog of human growth hormone (GH) that acts as a highly selective **Growth Hormone Receptor Antagonist**. 1. **Why Acromegaly is Correct:** In Acromegaly, there is an overproduction of GH (usually from a pituitary adenoma), leading to elevated levels of Insulin-like Growth Factor-1 (IGF-1). Pegvisomant binds to the GH receptor but prevents the functional dimerization and signal transduction required for IGF-1 production. Unlike Somatostatin analogs (e.g., Octreotide), which inhibit GH *secretion*, Pegvisomant blocks GH *action* at the periphery. It is primarily used for patients who are resistant to or intolerant of surgery, radiation, or somatostatin analogs. 2. **Why Other Options are Incorrect:** * **Parkinsonism:** Treated with dopaminergic agents (Levodopa) or anticholinergics. Pegvisomant has no effect on dopamine receptors or the basal ganglia. * **Hyperprolactinemia:** Managed with Dopamine Agonists (e.g., Cabergoline, Bromocriptine) which inhibit prolactin release from the pituitary. * **Amenorrhoea:** This is a clinical symptom often caused by hyperprolactinemia or PCOS. While Pegvisomant might indirectly help if acromegaly is the cause, it is not a standard treatment for amenorrhoea itself. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** GH Receptor Antagonist (prevents receptor dimerization). * **Monitoring:** Unlike other treatments, GH levels will remain high (or even increase) during therapy; therefore, **serum IGF-1 levels** are used to monitor treatment efficacy. * **Side Effect:** Potential for liver enzyme elevation; periodic LFT monitoring is required. * **Administration:** Subcutaneous injection.

Q: Onabotulinum toxin A can be used for the treatment of which of the following conditions?

Chronic migraine.. **Explanation:** **Onabotulinum toxin A** is a neurotoxin derived from *Clostridium botulinum*. It acts by cleaving the **SNAP-25 protein**, which prevents the fusion of synaptic vesicles with the neuronal membrane, thereby inhibiting the release of **Acetylcholine** at the neuromuscular junction. **Why Chronic Migraine is the Correct Answer:** While Botulinum toxin is used for various muscular conditions, the specific formulation **Onabotulinum toxin A** (Botox) is FDA-approved and specifically indicated for the prophylaxis of **Chronic Migraine** (defined as ≥15 headache days per month, with at least 8 being migraines, for >3 months). In this context, it is thought to work by inhibiting the release of nociceptive neuropeptides like **CGRP** (Calcitonin Gene-Related Peptide) and Substance P, thereby reducing peripheral and central sensitization. **Analysis of Other Options:** * **A, C, and D (Cervical dystonia, Blepharospasm, and Strabismus):** While Botulinum toxin is indeed used to treat these conditions, they are typically treated with various formulations (including AbobotulinumtoxinA or IncobotulinumtoxinA). In the context of standard medical examinations, when "Chronic Migraine" is provided as an option alongside focal dystonias, it highlights the specific, high-yield preventive indication for Onabotulinum toxin A that distinguishes it from purely motor-disorder treatments. **NEET-PG High-Yield Pearls:** * **Mechanism:** Proteolysis of SNAP-25 (SNARE protein). * **Clinical Use:** Achalasia cardia, Hyperhidrosis (excessive sweating), and Spasticity. * **Cosmetic Use:** Reduction of glabellar lines ("frown lines"). * **Contraindication:** Myasthenia Gravis and Eaton-Lambert Syndrome (due to pre-existing neuromuscular junction weakness). * **Antidote:** Botulism antitoxin (heptavalent).

Q: Local anaesthetics act by inhibiting which of the following?

Influx of sodium ions. **Explanation:** **Mechanism of Action:** Local anesthetics (LAs) act by blocking the **voltage-gated sodium channels** from the inner surface of the neuronal membrane. When a nerve is stimulated, sodium channels open to allow an **influx of sodium ions**, which causes depolarization and the generation of an action potential. LAs bind to the specific receptors within the sodium channel pore, preventing this influx. By inhibiting sodium entry, LAs prevent depolarization, thereby blocking nerve impulse conduction. **Analysis of Options:** * **Option C (Correct):** LAs specifically target the "activated" and "inactivated" states of sodium channels to prevent the **influx** of Na+ ions into the cell. * **Option A & B:** While sodium is a cation, these options are too vague. The specific mechanism is tied to the sodium ion species rather than general cation movement. * **Option D:** Efflux of sodium ions is mediated by the Na+/K+ ATPase pump to restore resting potential; LAs do not primarily act on this process to achieve anesthesia. **High-Yield NEET-PG Pearls:** * **State-Dependent Block:** LAs have a higher affinity for channels in the **open (activated)** and **inactivated** states rather than the resting state. This is why rapidly firing nerves are blocked faster (Use-dependent block). * **pH Dependency:** LAs are weak bases. In **acidic environments** (e.g., infected tissues/abscesses), LAs become ionized and cannot cross the lipid membrane, leading to reduced efficacy. * **Order of Blockade:** Small myelinated fibers > Small unmyelinated fibers > Large myelinated fibers. * **Sensitivity:** Pain > Temperature > Touch > Deep Pressure > Motor function.

Q: Ethosuximide is used in the treatment of which type of seizure?

Absence seizure. **Explanation:** **Ethosuximide** is the drug of choice for **Absence Seizures (Petit Mal)** [1]. **1. Why Absence Seizure is correct:** The pathophysiology of absence seizures involves abnormal T-type $Ca^{2+}$ currents in the thalamic neurons, which act as a pacemaker to generate the characteristic 3 Hz spike-and-wave discharges on EEG [2]. Ethosuximide works specifically by **inhibiting these T-type voltage-gated calcium channels** in the thalamus [1], thereby suppressing the rhythmic cortical discharges without significantly affecting other ion channels. **2. Why other options are incorrect:** * **Tonic-clonic (GTCS) and Partial Seizures:** These involve different mechanisms (primarily $Na^+$ channel overactivity). Ethosuximide has a very narrow spectrum and is ineffective against these seizures. Drugs like Valproate, Phenytoin, or Carbamazepine are preferred here. * **Myoclonic Seizures:** While Valproate is the drug of choice for myoclonic seizures, Ethosuximide does not provide the necessary broad-spectrum coverage required for this seizure type. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Ethosuximide is the DOC for pure absence seizures. However, if a patient has **concomitant** absence and GTCS, **Valproate** becomes the DOC. * **Side Effects:** Remember the mnemonic **EFGH** — **E**thesuximide causes **F**atigue, **G**I distress, **H**eadache (and rarely Hematologic issues like Stevens-Johnson Syndrome). * **EEG Finding:** Absence seizures are classically associated with **3 Hz spike-and-wave patterns** [2].

Q: Which of the following statements about phenytoin is true?

It follows zero-order kinetics.. ### Explanation **1. Why Option A is Correct:** Phenytoin exhibits a unique pharmacokinetic profile known as **Capacity-Limited Metabolism** (or Michaelis-Menten kinetics). At low therapeutic concentrations, it follows first-order kinetics. However, the hepatic enzymes responsible for its metabolism (CYP2C9 and CYP2C19) become saturated even at doses within the therapeutic range. Once saturated, the rate of metabolism becomes constant regardless of the plasma concentration, shifting to **Zero-Order Kinetics**. This is clinically significant because small dose increments can lead to disproportionately large increases in plasma levels, potentially causing toxicity. **2. Why the Other Options are Incorrect:** * **Option B:** Phenytoin is highly **teratogenic**. It is associated with **Fetal Hydantoin Syndrome**, characterized by craniofacial dysmorphism, hypoplastic phalanges/nails, and growth retardation. * **Option C:** Phenytoin is **extensively metabolized** in the liver (primarily by parahydroxylation). Less than 5% of the drug is excreted unchanged in the urine. * **Option D:** Phenytoin is a potent **Inducer of Microsomal Enzymes** (CYP450). This leads to significant drug-drug interactions, such as reducing the efficacy of oral contraceptives, warfarin, and steroids. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 10–20 µg/mL. * **Adverse Effects (Mnemonic: HOT MALAI):** **H**irsutism, **O**steomalacia, **T**eratogenicity, **M**egaloblastic anemia (folate deficiency), **A**taxia, **L**ymphadenopathy, **A**rrhythmias (on rapid IV), **I**nsulin inhibition (hyperglycemia), and **Gum Hyperplasia**. * **Fosphenytoin:** A water-soluble prodrug of phenytoin used for IV administration to avoid the risk of "Purple Glove Syndrome" and local irritation.

Q: Which drug requires visual field monitoring before starting treatment?

Vigabatrin. **Explanation:** **Vigabatrin (Option A)** is the correct answer because it is associated with a high risk of **permanent bilateral concentric visual field constriction** (peripheral vision loss). This occurs in approximately 30–50% of patients due to the accumulation of GABA in the retina, leading to retinal toxicity. Consequently, baseline visual field testing (perimetry) is mandatory before initiation, followed by monitoring every 6 months. **Why the other options are incorrect:** * **Topiramate (Option B):** While it can cause ocular side effects like acute myopia and secondary angle-closure glaucoma, it does not typically require routine visual field monitoring. Its most high-yield side effects are nephrolithiasis and cognitive "fogging." * **Valproic acid (Option C):** Primarily associated with hepatotoxicity, pancreatitis, and neural tube defects. It does not have significant ocular toxicity. * **Carbamazepine (Option D):** Known for causing diplopia and ataxia as dose-related side effects, but it does not cause permanent visual field defects requiring screening. **Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Vigabatrin is an irreversible inhibitor of **GABA-transaminase**, the enzyme responsible for GABA degradation. * **Drug of Choice:** It is the first-line treatment for **Infantile Spasms** (West Syndrome) associated with Tuberous Sclerosis. * **Mnemonic:** **Vi**gabatrin = **Vi**sual field loss (**Vi**-**Ga**-**B**atrin: **Vi**sual **Ga**ba **B**locker). * **Black Box Warning:** Due to the risk of permanent vision loss, it is often restricted to patients who have failed other treatments.

Q: Which of the following opioids is used via the transdermal route for malignancy-associated pain?

Fentanyl. **Explanation:** **Fentanyl** is the correct answer because it possesses the specific physicochemical properties required for effective transdermal delivery: **high lipid solubility** and **low molecular weight**. These characteristics allow it to penetrate the stratum corneum easily. In malignancy-associated chronic pain, the Fentanyl transdermal patch (Durogesic) provides a stable plasma concentration over 72 hours, offering a non-invasive alternative for patients with dysphagia or persistent nausea. **Why the other options are incorrect:** * **Morphine:** It is the gold standard for cancer pain (WHO Step 3) but is **hydrophilic**. Its poor lipid solubility makes it unsuitable for transdermal absorption; it is primarily administered orally or intravenously. * **Codeine:** A weak opioid (WHO Step 2) used for mild-to-moderate pain. It is a prodrug converted to morphine and is administered orally. * **Oxycodone:** A potent semi-synthetic opioid used for severe pain. While available in controlled-release oral formulations, it is not standardly used via the transdermal route. **High-Yield Clinical Pearls for NEET-PG:** * **Buprenorphine** is the only other opioid commonly used via a transdermal patch in clinical practice. * **Fentanyl Patch Timing:** It takes **12–24 hours** to reach peak plasma concentration; therefore, it is used for *chronic* stable pain, never for *acute* or breakthrough pain. * **Potency:** Fentanyl is approximately **75–100 times more potent** than Morphine. * **Safety:** Fentanyl is preferred over Morphine in patients with **renal failure** as it has no active metabolites (unlike Morphine-6-glucuronide).

Q: A 75-year-old male patient, started on new medications for Parkinson's disease, has begun gambling and making inappropriate sexual comments. Which medication is likely responsible for this change in behavior?

Ropinirole. **Explanation:** The patient is presenting with **Impulse Control Disorders (ICDs)**, characterized by behaviors such as pathological gambling, hypersexuality, compulsive shopping, and binge eating. **Why Ropinirole is correct:** Ropinirole is a **non-ergot Dopamine Agonist (DA)**. These agents have a high affinity for **D3 receptors**, which are primarily located in the **mesolimbic system** (the brain's reward pathway). Excessive stimulation of these receptors leads to behavioral disinhibition and the development of ICDs. While all dopamine-enhancing drugs can theoretically cause these side effects, non-ergot DAs (Ropinirole and Pramipexole) carry the highest risk, occurring in up to 14–17% of patients. **Analysis of Incorrect Options:** * **Levodopa + Carbidopa:** While Levodopa can cause ICDs (often termed "Dopamine Dysregulation Syndrome"), the risk is significantly lower than with dopamine agonists. It is more commonly associated with motor fluctuations and dyskinesias. * **Bromocriptine:** This is an ergot-derived dopamine agonist. While it can cause ICDs, it is less commonly used today due to risks of pulmonary and cardiac fibrosis, and its D3 selectivity is less pronounced than that of Ropinirole. * **Entacapone:** This is a COMT inhibitor used to prevent the peripheral breakdown of Levodopa. It does not directly stimulate dopamine receptors and is not a primary cause of ICDs. **High-Yield Clinical Pearls for NEET-PG:** * **D3 Receptors = Reward/Emotion:** Think "D3 for Desire." * **Management:** The first step in managing ICDs in Parkinson’s is to **taper and discontinue the Dopamine Agonist.** * **Pramipexole vs. Ropinirole:** Both are high-yield triggers for ICDs in exam questions. * **Risk Factors:** Younger age, male gender, and a pre-existing history of impulsive behavior or substance use.

Question 1

Which of the following statements regarding benzodiazepines is true?

Accepted Answer

These act as GABA facilitators.

Answer

These are very unsafe drugs.

Answer

These are powerful enzyme inducers.

Answer

The antidote for these is protamine sulfate.

Question 2

Pegvisomant is approved for the treatment of which condition?

Accepted Answer

Acromegaly

Answer

Parkinsonism

Answer

Hyperprolactinemia

Answer

Amenorrhoea

Question 3

Which of the following anticonvulsant drugs can cause granulocytopenia, gingival hyperplasia, and facial hirsutism?

Accepted Answer

Phenytoin

Answer

Valproate

Answer

Carbamazepine

Answer

Phenobarbitone

Question 4

Onabotulinum toxin A can be used for the treatment of which of the following conditions?

Accepted Answer

Chronic migraine.

Answer

Cervical dystonia.

Answer

Blepharospasm.

Answer

Strabismus.

Question 5

Local anaesthetics act by inhibiting which of the following?

Accepted Answer

Influx of sodium ions

Answer

Influx of intracellular cations

Answer

Efflux of intracellular cations

Answer

Efflux of sodium ions

Question 6

Ethosuximide is used in the treatment of which type of seizure?

Accepted Answer

Absence seizure

Answer

Tonic-clonic seizure

Answer

Myoclonic seizure

Answer

Partial seizure

Question 7

Which of the following statements about phenytoin is true?

Accepted Answer

It follows zero-order kinetics.

Answer

It is not teratogenic.

Answer

It is excreted unchanged in urine.

Answer

It does not induce microsomal enzymes.

Question 8

Which drug requires visual field monitoring before starting treatment?

Accepted Answer

Vigabatrin

Answer

Topiramate

Answer

Valproic acid

Answer

Carbamazepine

Question 9

Which of the following opioids is used via the transdermal route for malignancy-associated pain?

Accepted Answer

Fentanyl

Answer

Morphine

Answer

Codeine

Answer

Oxycodone

Question 10

A 75-year-old male patient, started on new medications for Parkinson's disease, has begun gambling and making inappropriate sexual comments. Which medication is likely responsible for this change in behavior?

Accepted Answer

Ropinirole

Answer

Levodopa + Carbidopa

Answer

Bromocriptine

Answer

Entacapone

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?